Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

BeyondSpring Inc (BYSI) USD0.0001

Sell:$15.25 Buy:$15.50 Change: $0.08 (0.52%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.08 (0.52%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.08 (0.52%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology cancer therapies. The Company’s lead product Plinabulin, is being studied in late-stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company's product, Plinabulin, is a marine-derived small-molecule with a range of biological activities. Plinabulin targets cells in the tumor vasculature resulting in selective anti-tumor activity. Plinabulin has also demonstrated a range of immuno-stimulatory effects, including stimulating the maturation of dendritic cells, increasing cytokine secretion, downregulating inhibitory T-cells, and stimulating tumor-antigen-specific T-cell activation.

Contact details

28 Liberty St Fl 39
United States
+1 (646) 5284184

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$592.60 million
Shares in issue:
39.12 million
Cayman Islands
US dollar

Key personnel

  • Huang Lan
    Chairperson of the Board, Chief Executive Officer, Co-Founder
  • Elizabeth Czerepak
    Chief Financial Officer
  • Richard Daly
    Chief Operating Officer
  • Ramon Mohanlal
    Chief Medical Officer and Executive Vice President of Research and Development, Director
  • G. Kenneth Lloyd
    Chief Scientific Officer
  • Gordon Schooley
    Chief Regulatory Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.